Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trial

Autor: Hermine I Brunner, Ivan Foeldvari, Ekaterina Alexeeva, Nuray Aktay Ayaz, Inmaculada Calvo Penades, Ozgur Kasapcopur, Vyacheslav G Chasnyk, Markus Hufnagel, Zbigniew Żuber, Grant Schulert, Seza Ozen, Adelina Rakhimyanova, Athimalaipet Ramanan, Christiaan Scott, Betul Sozeri, Elena Zholobova, Ruvie Martin, Xuan Zhu, Sarah Whelan, Luminita Pricop, Alberto Martini, Daniel Lovell, Nicolino Ruperto

Publikováno v: ANNALS OF THE RHEUMATIC DISEASES
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname

BackgroundTreatment options in patients with enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (JPsA) are currently limited. This trial aimed to demonstrate the efficacy and safety of secukinumab in patients with active ERA and JPsA

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ef5fc478d191a1a825193d368ce96f27
https://doi.org/10.1136/ard-2022-222849